维奈克拉片 | China Drugs ListVenetoclax tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
其他
- 商品名
- Venclexta / Venclyxto
- 企业
- AbbVie Inc. (美国说明书); AbbVie Deutschland GmbH & Co. KG (欧盟上市许可持有人)AbbVie Inc. (US label); AbbVie Deutschland GmbH & Co. KG (EU authorization holder)
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 美国处方资料：用于成人慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。也与阿扎胞苷、地西他滨或低剂量阿糖胞苷联合，用于75岁及以上成人，或因合并症无法接受强化诱导化疗的成人新诊断急性髓系白血病。这些为美国适应症，不代表已核实中国说明书。US prescribing information: adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Also, with azacitidine, decitabine or low-dose cytarabine, for newly diagnosed acute myeloid leukemia in adults aged 75 years or older, or adults with comorbidities that prevent intensive induction chemotherapy. These are US indications, not verification of Chinese labeling.
- 适应症来源与口径
- 修订于 05/2026. 部分境外适应症；不确立中国批准范围。Revised 05/2026. Selected overseas indications; does not establish the Chinese approved scope.
- 说明书信息局限
- 已链接境外官方处方资料；尚未核实完整的现行中国说明书。Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- 中国可获得性状态
- 本次英文来源核查未独立核实中国批准、现行中国适应症及持续在售情况。Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
- 海外状态
- 请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异；尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- 医保分类
- 尚未核实Not yet verified
- 医保版本
- 中国国家医保信息待核实Chinese national insurance review pending
- 医保核查说明
- 本次新增记录尚未确定报销资格；缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.
来源
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208573s032lblCorrected.pdf
- Venclexta——美国完整处方资料Venclexta — US full prescribing information
Official prescribing information · Revised 05/2026
已打开FDA网站上的完整说明书，核对适应症及BCL-2机制。美国适用范围不确立中国批准。Complete FDA-hosted label opened; indications and BCL-2 mechanism checked. US scope does not establish Chinese approval.
- Venclexta / Venclyxto——EMA欧洲公开评估报告Venclexta / Venclyxto — EMA European public assessment report
Regulatory medicine overview · Web page accessed 2026-11-02
已打开并核查英文监管一手来源。此处报告部分欧盟适应症及欧盟许可持有人；不作为中国批准证据。English primary regulatory source opened and reviewed. Selected EU indications and the EU authorization holder are reported; this is not evidence of Chinese approval.
证据核查日期：